Dr. Thomas E. Lowe, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
3285 Skypark Dr
Torrance, CA 90505
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, Geffen School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 497
Licensed in California since 2004, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of California, Geffen School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license A86789 (first issued 2004; current) -
Internal Medicine Physician
CA license A86789 (first issued 2004; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Torrance Memorial Medical Center Torrance, CA
- Providence Little Company of Mary Med Ctr Torrance Torrance, CA
Medical groups
- Torrance Health Association Inc (299 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 497
- Services billed
- 195,635
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, oxaliplatin, 0.5 mg | 32,207 | 14 |
| Injection, fosaprepitant, 1 mg | 27,600 | 31 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 17,452 | 30 |
| Injection, granisetron hydrochloride, 100 mcg | 2,730 | 40 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,488 | 38 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,676 | 359 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 670 | 40 |
| Established patient office or other outpatient visit, 20-29 minutes | 549 | 328 |
| Administration of chemotherapy into vein, 1 hour or less | 434 | 54 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 428 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Torrance, CA | 89 |
| Hydroxyurea Other prescribers in Torrance, CA | 71 |
| Dexamethasone Other prescribers in Torrance, CA | 61 |
| Tamoxifen Citrate Other prescribers in Torrance, CA | 59 |
| Eliquis (apixaban) Other prescribers in Torrance, CA | 56 |
| Lenalidomide | 51 |
| Prochlorperazine Maleate Other prescribers in Torrance, CA | 50 |
| Revlimid (lenalidomide) | 50 |
| Acyclovir Other prescribers in Torrance, CA | 46 |
| Ondansetron Odt (ondansetron) Other prescribers in Torrance, CA | 37 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 25 payments worth $577 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $160 |
|---|---|
| Genentech USA, Inc. | $101 |
| Array Biopharma Inc | $80.11 |
| Puma Biotechnology, Inc. | $60.47 |
| Janssen Biotech, Inc. | $49.87 |
| Celgene Corporation | $32.34 |
| Aimmune Therapeutics, Inc. | $30.77 |
| Merck Sharp & Dohme LLC | $27.06 |
| Food and Beverage | $577 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $75,886 in research payments for these studies, mostly to the institutions running them.
- Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06
Genentech, Inc. - To assess the efficacy and safety of AZD9291 versus Placebo in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB IIIA non small cell lung carcinoma following complete tumour resection with or w…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.